Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
A phase 2/3 trial of Margetuximab, Retifanlimab and Trastuzumab in HER2-positive gastric cancer, run by MacroGenics, completed.
Overview
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer is a phase 2/3 interventional study registered as NCT04082364 by MacroGenics, with 82 participants recorded, started 2019-09-30 and reaching its primary completion in 2024-01-15. Interventions recorded: margetuximab, Retifanlimab, Tebotelimab, Trastuzumab, Chemotherapy. Conditions recorded: Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer.
Linked to the drug Margetuximab because the registry names it among its interventions and HER2-positive gastric cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialMargetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Shares MacroGenics, Margetuximab, Trastuzumab and the tag pipeline.
- TrialMARGetuximab Or Trastuzumab (MARGOT)
Shares Margetuximab, Trastuzumab and the tag pipeline.
- TrialStudy of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Shares Retifanlimab and the tag pipeline.
- TrialStudy of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Shares Retifanlimab and the tag pipeline.
- TreatmentLorigerlimab
Shares MacroGenics and the tag pipeline.
- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares HER2-positive gastric cancer, Trastuzumab and the tag pipeline.
- TrialTherapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
Shares HER2-positive gastric cancer and the tag pipeline.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares HER2-positive gastric cancer, Trastuzumab and the tag pipeline.